Keyword: Novartis

Novartis hopes its MS drug siponimod’s performance can help secure a blockbuster approval. And now it has more data to back it up.

Novartis’ prospects for launching a copy of GlaxoSmithKline’s Advair this year just went from highly unlikely to not happening.

Novartis investors' discontent with first-quarter results shows how much they're expecting of new CEO Vas Narasimhan.

Not even two months into a probe of officials accused of taking Novartis bribes, Greece's parliament is handing off the investigation.

Eli Lilly’s first oncology campaign launched last week, putting the drugmaker on a growing list of pharma companies running DTC ads for cancer drugs.

Novartis CEO Vas Narasimhan has joined the chorus calling for the U.S. to step up on biosimilar market access, stat.

Novartis faces doctor kickback allegations in China, Samsung and AbbVie ink a Humira biosim settlement, and Takeda seeks financing for a Shire bid.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's requested add-on payment.